ClinicalTrials.gg
Sign In

Drug

C-Met Inhibitor ANS014004 clinical trials

Also written ANS014004.

studies test it
3
open now
2
in phase 3
0
first study started
2024

Keep track of what changes. Save the c-Met Inhibitor ANS014004 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

ANS014004
2

Combined with it in one product

ANS014004 + PLB1004
1

Studies by the year they started

3 studies that test it; most in 2024 (2)

Studies that test c-Met Inhibitor ANS014004, by start year
YearStudies
20242
20261

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung
1

Who runs them

Industry 3 · Other 0

Avistone Biotechnology Co., Ltd. (2) · Beijing Pearl Biotechnology Limited Liability Company (1)

Often tested with

Tested in the same studies.

Andamertinib (1)

Studies

Open first, then newest update. How each study uses c-Met Inhibitor ANS014004 is read from its arms, and is right about nine times in ten.

Testing it · 3